Science 1st: Obesity & Metabolic Diseases

Add this event to your calendar:
24/05/2017 16:00 24/05/2017 19:00 America/New_York Science 1st: Obesity & Metabolic Diseases JLABS @ M2D2 , 110 Canal Street, 4th Floor , Lowell , MA 01852 Johnson & Johnson Innovation, JLABS false DD/MM/YYYY

Science 1st: Obesity & Metabolic Diseases

JLABS @ M2D2 , 110 Canal Street, 4th Floor , Lowell , MA 01852

May 24, 2017 from 16:00 PM to 19:00 PM (EST)

$10 - $35

Science 1st: Obesity & Metabolic Diseases
Evidence-based development of mechanisms driving new technologies and therapies

What does the future look like in the fight against obesity and metabolic disease? Rising rates of obesity impact our collective health, quality of life, and economic health burden. However, treatments and understanding of therapeutic mechanisms are limited. Although there have been many attempts at therapeutic treatments, the current landscape remains greatly unchanged. When will we unlock this disease state and deliver stage-appropriate diagnosis and effective treatment solutions?

Bariatric surgery is promising, and possible mechanisms of action have come to light through recent research, as investigations and discovery have deepened mechanism-based understanding. Some solutions are proving both effective and durable. Is this the start of the transformation needed to address the obesity epidemic?

This event will tackle the following questions:

  • What makes mechanisms driving effective metabolic treatment so elusive?
  • What are recent discoveries and areas of research that have the most potential to deliver solutions?
  • What do the future of obesity and metabolic treatment therapy look like? Is it staged?

Miguel Alonso-Alonso | Assistant Professor of Surgery, Beth Israel Deaconess Medical Center read bio»
Elisa Fabbrini | Associate Director, Metabolism, Janssen Pharmaceutical Companies of Johnson & Johnson read bio»
Nicholas Stylopoulos | Assistant Professor, Boston Children’s Hospital - Harvard Medical School read bio»
Christopher Thompson | Principle Investigator, Developmental Endoscopy
[moderator] Bethany Grant | Director R&D, Surgical Innovation, Ethicon, Inc. read bio»

2:00 PM | Registration Opens and Networking
2:30 PM | Presentations
3:15 PM | Panel Discussion
4:00 PM | Networking Reception
5:00 PM | Program Close

$25 | General Public
$10 | Student/Academic
$35 | At the door

110 Canal Street, 4th Floor
Lowell, MA

Speakers' Biographies:
Miguel Alonso-Alonso, MD PhD | Assistant Professor of Surgery, Beth Israel Deaconess Medical Center
Dr. Alonso-Alonso is an Assistant Professor of Surgery at Harvard Medical School and Beth Israel Deaconess Medical Center, where he leads a multidisciplinary team dedicated to study the neurocognitive bases of human eating behavior and obesity, and the relationship between nutrition and brain function. In particular, Dr. Alonso-Alonso is interested in the role of self-regulatory processes and executive functions in the support and maintenance of healthy eating behaviors and the implications for obesity and its treatment. In recent years he has conducted pioneering computational modeling work and clinical studies with noninvasive neuromodulation of the prefrontal cortex in obesity. Dr. Alonso-Alonso‘s research also includes the development and use of computerized neuropsychological tests, functional neuroimaging and laboratory studies on human eating behavior with human-computer interaction technologies and intrameal neurocognitive monitoring.
A native of Galicia, in northwest Spain, Dr. Alonso-Alonso is board certified in Neurology, and holds a PhD in Medicine / Psychiatry and Clinical Psychobiology from the University of Barcelona and Master's degrees in Clinical Neuroscience and Clinical Research from University College London and Harvard-MIT Division of Health Sciences and Technologies. During his career he has published more than 30 papers, with 1271 accumulated citations to date and has received multiple fellowships and awards.
Connect with Miguel:   Connect on LinkedIn

Elisa Fabbrini | Associate Director, Metabolism, Janssen Pharmaceutical Companies of Johnson & Johnson
Elisa Fabbrini obtained her MD and PhD in endocrinology and metabolism from the University of Rome La Sapienza. She then moved to Washington University in St Louis, MO, where she trained under the mentorship of Dr. Samuel Klein in the use of stable isotope techniques to evaluate substrate metabolism in humans in vivo. During the 11 years she was at Washington University, first as a postdoctoral fellow and then as a faculty member, her research focused on the pathophysiology of obesity, type 2 diabetes, insulin resistance, and ectopic fat distribution. Elisa contributed to several important and novel observations in the field of obesity pathophysiology and metabolic disease. In particular, she has identified that: i) intrahepatic fat is a fundamental marker, and an important component, of obesity-associated metabolic dysfunction (impaired multi-organ insulin sensitivity and alterations in very-low density lipoprotein kinetics); ii) alterations in tissue fatty acid transport are involved in the pathogenesis of ectopic triglyceride accumulation and metabolic disease; iii) adipose tissue of obese people with metabolic disease is enriched with particular immune cells type which are involved in the pathogenesis of metabolic disease; iv) obese people without metabolic disease are resistant, whereas obese people with metabolic disease are prone, to the deleterious effects of weight gain. Two years ago, Elisa joined the Metabolism group at Janssen R&D, where she works in the diabetes late development program.
Connect with Elisa:   Connect on LinkedIn

Nicholas Stylopoulos | Assistant Professor, Boston Children’s Hospital - Harvard Medical School
Dr. Stylopoulos is a Principal Investigator in the Division of Endocrinology and the Center for Basic and Translational Obesity Research at Boston Children’s Hospital (BCH) and an Assistant Professor at Harvard Medical School. He is also an Associate member of the Broad Institute of MIT and Harvard. His laboratory focuses on the development of new treatments for obesity, diabetes and other metabolic diseases. They currently study the physiological and molecular effects and mechanisms of action of weight loss surgery. The work of the lab has been published in high impact scientific journals and has been highlighted by several national and international media outlets.
Connect with Nicholas:   Connect on LinkedIn

Bethany Grant | Director R&D, Surgical Innovation, Ethicon, Inc.
Bethany Grant is the R&D Director of Surgical Innovation for Metabolics at Ethicon, a company in the Medical Device division of Johnson & Johnson. In this role she is working to identify unmet needs in metabolic diseases and obesity and to develop treatments that address these needs. Bethany started her career in the Aerospace Industry; after completing her B.S. and M.S. in Aero/Astro Engineering at MIT, she spent time at Boeing Defense and Space and Loral Space Systems designing composite structures for helicopters and satellites. Through her work at a product development consulting firm focusing mainly on the healthcare industry, Bethany helped launch a custom dental abutment from concept to a successful business solution and acquisition by AstraZeneca. After the integration, Bethany joined J&J with the orthopedic business, spending 5 years with DePuy Synthes Mitek Sports Medicine. In this role, she developed minimally invasive orthopedic procedural solutions for joint soft tissue repair, with a focus on hip arthroscopy. Bethany has worked for over 20 years in all phases of product development, from early stage to launch, and in many sizes of organizations.
Connect with Bethany:   Connect on LinkedIn

Johnson & Johnson Innovation, JLABS

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), New York City, and with Shanghai opening in 2019. For more information please visit or follow @JLABS.

Event contact

Related content